88 related articles for article (PubMed ID: 22645747)
1. VEGF is clearly an exciting point of attack in the treatment of neovascular diseases of the retina and choroid.
Coimbra JC
Ophthalmologica; 2012; 227 Suppl 1():1. PubMed ID: 22645747
[No Abstract] [Full Text] [Related]
2. Vascular endothelial growth factors in retinal and choroidal neovascular diseases.
Kinnunen K; Ylä-Herttuala S
Ann Med; 2012 Feb; 44(1):1-17. PubMed ID: 21284527
[TBL] [Abstract][Full Text] [Related]
3. [Experience with vascular endothelial growth factor inhibitors used in ophthalmologic care].
Khalaim AV; Stoliarenko GE
Vestn Oftalmol; 2007; 123(5):54-6, preceding 56. PubMed ID: 18078062
[No Abstract] [Full Text] [Related]
4. An evidence-based review of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 2. Coats' disease, best disease, and uveitis with childhood neovascularization.
Chaudhary KM; Mititelu M; Lieberman RM
J Pediatr Ophthalmol Strabismus; 2013; 50(1):11-9. PubMed ID: 22938515
[TBL] [Abstract][Full Text] [Related]
5. Systemic safety of bilateral intravitreal anti-vascular endothelial growth factor injections.
Freund KB; Vance SK
Retina; 2011 Jan; 31(1):1-3. PubMed ID: 21187729
[No Abstract] [Full Text] [Related]
6. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice.
Dejneka NS; Kuroki AM; Fosnot J; Tang W; Tolentino MJ; Bennett J
Mol Vis; 2004 Dec; 10():964-72. PubMed ID: 15623986
[TBL] [Abstract][Full Text] [Related]
7. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy.
Zhang SX; Ma JX
Prog Retin Eye Res; 2007 Jan; 26(1):1-37. PubMed ID: 17074526
[TBL] [Abstract][Full Text] [Related]
8. Limited long-term efficacy of intravitreous anti-VEGF pharmacotherapy in sarcoidosis complicated by peripapillary choroidal neovascular membrane.
Shah SP; Hubschman JP; Bourges JL; Hu AY; Schwartz SD
Acta Ophthalmol; 2010 Sep; 88(6):e243-4. PubMed ID: 19740129
[No Abstract] [Full Text] [Related]
9. Ocular neovascularization: basic mechanisms and therapeutic advances.
Dorrell M; Uusitalo-Jarvinen H; Aguilar E; Friedlander M
Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S3-19. PubMed ID: 17240254
[TBL] [Abstract][Full Text] [Related]
10. Photodynamic therapy in the anti-VEGF era.
Fine HF
Br J Ophthalmol; 2007 Jun; 91(6):707-8. PubMed ID: 17510474
[TBL] [Abstract][Full Text] [Related]
11. Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis.
Todorich B; Yiu G; Hahn P
Expert Rev Clin Pharmacol; 2014 May; 7(3):375-91. PubMed ID: 24580084
[TBL] [Abstract][Full Text] [Related]
12. Retinal and choroidal microangiopathies: therapeutic opportunities.
Afzal A; Shaw LC; Ljubimov AV; Boulton ME; Segal MS; Grant MB
Microvasc Res; 2007; 74(2-3):131-44. PubMed ID: 17585951
[TBL] [Abstract][Full Text] [Related]
13. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study.
Sadda SR; Stoller G; Boyer DS; Blodi BA; Shapiro H; Ianchulev T
Retina; 2010 Oct; 30(9):1390-9. PubMed ID: 20924261
[TBL] [Abstract][Full Text] [Related]
14. Resolution of choroidal neovascularization secondary to punctate inner choroidopathy (PIC) with intravitreal anti-VEGF agents: a case series.
Mangat SS; Ramasamy B; Prasad S; Walters G; Mohammed M; Mckibbin M
Semin Ophthalmol; 2011 Jan; 26(1):1-3. PubMed ID: 21275596
[TBL] [Abstract][Full Text] [Related]
15. Quantitative physiological measurements to evaluate the response of antivascular endothelial growth factor treatment in patients with neovascular diseases.
Hong IH; Park SP
Indian J Ophthalmol; 2017 Jul; 65(7):559-568. PubMed ID: 28724811
[TBL] [Abstract][Full Text] [Related]
16. Ranibizumab for retinal neovascularization.
Jorge R; Oliveira RS; Messias A; Almeida FP; Strambe ML; Costa RA; Scott IU
Ophthalmology; 2011 May; 118(5):1004-1004.e1. PubMed ID: 21539985
[No Abstract] [Full Text] [Related]
17. Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein.
Akiyama H; Mohamedali KA; E Silva RL; Kachi S; Shen J; Hatara C; Umeda N; Hackett SF; Aslam S; Krause M; Lai H; Rosenblum MG; Campochiaro PA
Mol Pharmacol; 2005 Dec; 68(6):1543-50. PubMed ID: 16150930
[TBL] [Abstract][Full Text] [Related]
18. Anti-VEGF treatment for subfoveal idiopathic (type II) choroidal neovascular membranes.
Hsing YE; Lee LR
Clin Exp Optom; 2012 Sep; 95(5):544-7. PubMed ID: 22738116
[TBL] [Abstract][Full Text] [Related]
19. Perfused, but not leaking.
Prenner JL; Kaiser R; Chang TS
Ophthalmology; 2009 Aug; 116(8):1590, 1590.e1-2. PubMed ID: 19651318
[No Abstract] [Full Text] [Related]
20. [Anti VEGF therapy in different forms of wet ARMD].
Panait OM
Oftalmologia; 2011; 55(4):17-9. PubMed ID: 22642131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
